中韩两国都具有丰富的天然产物资源及独特的开发利用经验。在本合作交流项目候选药用植物的药物研发模式下，共同致力于植物雌激素类药用资源在女性健康领域的应用和开发，形成专利和技术转让，加快药物研发，有望带动医药生物资源的新需求，促进两国经济发展。项目将整合天津中医药大学和淑明女子大学各自优势，通过对4种泛亚地区候选药用植物的化学指纹分析、活性成分与原材料的标准化以及药效与安全性评价研究，共同促使形成可与制药企业对接的具有神经保护作用、改善更年期女性生活的植物雌激素类药物。中方将负责其化学分析及植物原料的标准化，包括1)标准提取物及组分的化学分析、分离和制备；2)标准实验方法的验证，为后续候选植物的质量控制铺垫，3)主要活性化合物的代谢物鉴定、体内外定性定量分析及分析方法的验证、及DMPK研究。韩方将负责利用体内外神经模型进行活性筛选，包括1) 大鼠或ER(α/β) KO小鼠模型和中风模型进行雌激素样作用体内外活性评价及信号通路研究；2)临床前安全性药理评价；3)基于生物标志物的全身生物影像学分析。双方将共同完成申请专利并取得相关国家资源开发许可，促进技术转让，为商品化药物开发提供基础技术支持

China and South Korea both have a wealth of natural resources and unique product-development experience. This project will integrate Tianjin University of Traditional Chinese Medicine and Sookmyung Women's University’s respective advantages to research and develop four pan-Asian medicinal plants in order to discover novel neuroprotective phytoestrogens. The Chinese team will be responsible for standardized extraction, chemical analysis, and large-scale preparation of active components; establishing quality control methods and standards; identification of main active metabolites, and DMPK studies. The ROK team will use in vivo and in vitro models of neuro- protection and estrogenic activity screens as well as biomarker-based bio-imaging for pharmacological analysis, MOA investigation, and safety pharmacology evaluation. The two sides will work together to complete the application and obtain the relevant patent license; to build a shared chemical library of phytoestrogens; and to provide basic technical support for the technology transfer, commercialization and expand cooperation with the relevant pharmaceutical companies.